What is Esperion Therapeutics's SG&A?

Esperion Therapeutics (ESPR) reported SG&A of $43.12M in Q1 2026.

How has Esperion Therapeutics's SG&A changed year-over-year?

Esperion Therapeutics's SG&A increased by 0.3% year-over-year, from $43M to $43.12M.

What is the long-term trend for Esperion Therapeutics's SG&A?

Over 4 years (2021 to 2025), Esperion Therapeutics's SG&A has grown at a -2.7% compound annual growth rate (CAGR), from $184.99M to $165.79M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Esperion Therapeutics ESPR SG&A

SG&A at other companies

AmgenAMGN

$1.6B-5.0%

Regeneron PharmaceuticalsREGN

$647.7M+2.3%

NewAmsterdam Pharma CompanyNAMS

$23.45M-13.6%

Lexicon PharmaceuticalsLXRX

$9.23M-20.5%

Zevra Therapeutics, Inc.ZVRA

$20.78M+6.3%

BridgeBio PharmaBBIO

$163.9M+54.1%

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's SG&A?: Esperion Therapeutics (ESPR) reported SG&A of $43.12M in Q1 2026.
How has Esperion Therapeutics's SG&A changed year-over-year?: Esperion Therapeutics's SG&A increased by 0.3% year-over-year, from $43M to $43.12M.
What is the long-term trend for Esperion Therapeutics's SG&A?: Over 4 years (2021 to 2025), Esperion Therapeutics's SG&A has grown at a -2.7% compound annual growth rate (CAGR), from $184.99M to $165.79M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.